Is Semaglutide a GLP-1 Agonist, and What Does That Mean for Weight Loss?

Step 1: what GLP-1 actually does in the body

Every time you eat, your gut releases GLP-1 into the bloodstream. The hormone signals the pancreas to release insulin in proportion to rising blood sugar, tells the brain that food has arrived, and slows the rate at which the stomach empties. All of this combines to reduce appetite and help you feel full sooner. The problem is that natural GLP-1 is broken down within minutes, so its influence is brief.

Semaglutide is engineered to resist that rapid breakdown. Its molecular structure is close enough to human GLP-1 to activate the same receptor, but different enough that enzymes take far longer to clear it. A single weekly injection maintains a steady level in the bloodstream throughout the week. You can read a plain-language overview of how this works on the Wegovy treatment page, or explore the broader category on our GLP-1 agonist and Wegovy page.

The NHS medicines page for semaglutide gives a patient-level explanation of the mechanism alongside guidance on side effects and storage.

Step 2: the licensed distinction between weight management and diabetes

Semaglutide is a GLP-1 agonist used across two separate licensed indications in the UK, and it is worth being clear on which is which. Wegovy (semaglutide 2.4mg weekly injection) is licensed for weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure or high cholesterol. Ozempic is also semaglutide, but it is licensed for type 2 diabetes — it is not licensed or recommended for weight loss, regardless of what you may have read online.

An oral form, Wegovy tablets, received MHRA approval in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. Its maintenance dose is 25mg taken once daily. The page on whether Wegovy is a dual agonist covers the single-versus-dual receptor question in more detail, which is a common point of confusion for people comparing their options.

A question our prescribers hear regularly: "Is the Wegovy I read about the same molecule as Ozempic?" The answer is yes, same molecule, different doses, different licences. The distinction is not a technicality, it shapes who a prescriber can appropriately treat and how.

Step 3: what the evidence shows at the GLP-1 receptor level

Because semaglutide activates only the GLP-1 receptor, it is categorised as a single-agonist. That is meaningful when comparing it with tirzepatide, which also activates the GIP receptor and is sold as Mounjaro. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. A higher 7.2mg dose of Wegovy, approved by the MHRA in January 2026, narrows that gap somewhat, with trials reporting around 20.7% average weight loss at 72 weeks.

For semaglutide specifically, the STEP 1 trial (68 weeks, semaglutide 2.4mg weekly, adults with obesity and no diabetes) showed roughly 15% average body-weight reduction compared with placebo. Those figures come from clinical populations alongside structured lifestyle support, and individual results vary. The STEP 1 paper in the New England Journal of Medicine is publicly accessible if you want to read the methodology. Our semaglutide overview brings together the key figures in one place.

One practical check worth doing: if you are already taking any other medicines, note them down before your consultation. Drug interactions and contraindications are among the first things a prescriber works through, and having a list ready saves time. It takes under a minute to photograph your repeat prescription or medicines cabinet.

For context on how private treatment is priced, the Wegovy pricing page covers what a legitimate private prescription typically includes and why cost varies by dose and provider. If you are based in Yorkshire and want to know more about accessing treatment locally, our Wegovy Leeds page explains the options available in the city. If you're ready to talk through your own situation, start your free consultation and a GPhC-registered prescriber will review your answers the same day.